Human epidermal receptor (HER) 2-positive advanced gastric cancer is one of the major subtypes of gastric cancer, accounting for ~20% of all cases. Although combination therapy with trastuzumab and chemotherapy provides meaningful survival benefit, clinical trials targeting HER2 have failed to demonstrate clinical benefits in first- or subsequent-line treatment. Trastuzumab deruxtecan, an antibody–drug conjugate, has shown positive results even in later-line treatment and has become new standard treatment. In first-line therapy, combination therapy with pembrolizumab and trastuzumab plus chemotherapy demonstrated a dramatic response rate. Therefore, the FDA rapidly approved it without waiting for the results of survival time. The emergence of combination therapy including immunotherapy with HER2-targeting agents and the development of HER2 targeting agents with or without immunotherapy have been advancing for treating HER2-positive gastric cancer. In this review, we will discuss the current status of treatment development and future perspectives for HER2-positive gastric cancer.
人表皮生长因子受体2（HER2）阳性晚期胃癌是胃癌的主要亚型之一，约占所有病例的20%。尽管曲妥珠单抗联合化疗方案能带来显著的生存获益，但针对HER2的临床试验在一线或后续治疗中均未能显示出临床效益。抗体偶联药物德曲妥珠单抗即使在后期治疗中也显示出积极疗效，已成为新的标准治疗方案。在一线治疗中，帕博利珠单抗联合曲妥珠单抗及化疗方案展现出显著的治疗反应率。因此，美国食品药品监督管理局在未等待生存时间结果的情况下迅速批准了该方案。包含免疫治疗与HER2靶向药物的联合治疗方案的出现，以及HER2靶向药物（无论是否联合免疫治疗）的研发进展，正在推动HER2阳性胃癌治疗领域的发展。本综述将探讨HER2阳性胃癌治疗的研发现状及未来展望。
Recent Progress in Treatment for HER2-Positive Advanced Gastric Cancer
肿瘤(癌症)患者之家